Alvogen and Dr Reddy’s US Suboxone Rivals Face Off Against Sandoz’ Authorized Generic
Alvogen and Dr Reddy’s have launched generic versions of Indivior’s Suboxone in the US, after the Supreme Court denied the originator’s attempt to further frustrate generic launches. But these two versions will compete with an authorized generic launched by Indivior through Sandoz.
You may also be interested in...
Indivior is working on receiving ex-US approvals for its opioid abuse treatment products and building its cash reserves but faces future uncertainty over US generic competition and a US Department of Justice legal action.
Firms that achieved recognition at last year’s Global Generics & Biosimilars Awards have continued to build on that success in the months since.
Alvogen and Dr Reddy’s do not infringe key patents protecting Indivior’s Suboxone Film, the US Court of Appeals has confirmed. But Teva continues to fall foul of a production patent running until 2024.